As Ebola Outbreak Continues, Biotech Firms See Stock Rise
International Business Times
Published Aug 27, 2014 05:01PM ET
Updated Aug 27, 2014 05:45PM ET
As Ebola Outbreak Continues, Biotech Firms See Stock Rise
By Kathleen Caulderwood -
The Ebola virus still sweeping across West Africa has already taken at least 1,350 lives and is costing the affected countries dearly. But on Wall Street, biotech companies such as Tekmira Pharmaceuticals Corp. TSE:TKM NASDAQ:TKMR and NewLink Genetics Corp NASDAQ:NLNK, which are currently working on Ebola research, have seen stock prices jump as investors bet on a possible cure for the largest Ebola outbreak in history.
The Vancouver-based Tekmira struck a $140 million contract with the U.S. Department of Defense four years ago to develop its treatment, called TKM-Ebola. Now the drug has emerged as one of the leading candidates for possible experimental use.
The company’s stock price is up 147 percent since the beginning of 2014 and experienced a 62 percent spike between March 3 and March 11, when the outbreak first began.
Unlike other experimental treatments such as Mapp Pharmaceuticals’ ZMapp, which is currently being used, Tekmira’s treatment has already begun human trials. The U.S. Food and Drug Administration put a “clinical hold” on the product in July, but earlier this month modified the designation to a “partial” hold, which may allow it to be used within the next few weeks.
“This current outbreak underscores the critical need for effective therapeutic agents to treat the Ebola virus,” Tekmira’s CEO said earlier this month. “We recognize the heightened urgency of this situation, and are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols.”
Meanwhile, NewLink is an Ames, Iowa-based firm that has seen its stock price jump 34 percent in the past four weeks. Most of its products in development are meant to treat cancer, but earlier in August, a company subsidiary, BioProtection Systems Corporate, announced a $1 million contract with the United States Defense Threat Reduction Agency (DTRA) for research on an Ebola vaccine.
“There is an urgent need for a medical countermeasure against the deadly Ebola virus,” NewLink CEO Dr. Charles Link said, according to a company press release.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.